Vicarious Surgical Receives NYSE Delisting Notice: Key Insights for Investors
Vicarious Surgical Receives NYSE Delisting Notice; Trading Moves to OTCID
Key Points from the Report
-
Vicarious Surgical Inc. (NYSE: RBOT) has received a delisting notice from the New York Stock Exchange (NYSE) after failing to meet the continued listing standard requiring a minimum average global market capitalization of \$15 million over a consecutive 30 trading day period, as dictated by Section 802.01B of the NYSE Listed Company Manual.
-
Trading on RBOT stock was suspended on the NYSE after market close on March 3, 2026.
-
The NYSE will apply to the SEC to officially delist Vicarious Surgical’s common stock once all relevant procedures, including any company appeals, are completed. The company has ten business days from receipt of the notice to file an appeal and is currently evaluating its options.
-
Vicarious Surgical has secured approval for its shares to be quoted on the OTCID market, operated by OTC Markets Group, Inc., effective March 4, 2026. The stock will continue trading under the ticker symbol “RBOT.”
What Shareholders Need to Know (Price Sensitive Information)
-
This delisting is a significant event that could impact the value and liquidity of Vicarious Surgical shares. Transitioning from a major exchange like NYSE to the OTCID may lead to reduced trading volume, potential price volatility, and decreased visibility among institutional investors.
-
The company is considering whether to appeal the NYSE’s delisting decision. If an appeal is filed and successful, it could potentially restore the company’s NYSE listing, but there is no guarantee of success.
-
Shareholder communication will continue via the company’s investor relations website, LinkedIn, and X (formerly Twitter) accounts. Investors are advised to monitor these channels for timely updates.
-
The company emphasized in its forward-looking statements that there are significant risks and uncertainties ahead, including regulatory approval for its surgical robotics systems, financing needs, competitive pressures, and market conditions.
Company Overview and Future Outlook
Founded in 2014 and headquartered in Waltham, Massachusetts, Vicarious Surgical is a next-generation surgical robotics company. It aims to revolutionize minimally invasive surgery by virtually transporting surgeons inside the patient using proprietary human-like robots. The company has strong backing from notable investors, including Bill Gates, Khosla Ventures, Innovation Endeavors, AME Cloud Ventures, Sun Hung Kai & Co. Ltd, and E15 VC.
The company cautions that its future performance depends on several factors: the success of its Vicarious Surgical System and other product candidates, the ability to secure regulatory approvals, the outcome of any potential appeal with the NYSE, future fundraising efforts, and the overall economic and market environment.
Forward-Looking Statements
The press release includes forward-looking statements regarding the timing of the OTCID quotation, the potential for an NYSE delisting appeal, and future business prospects. However, these statements are subject to significant risks, uncertainties, and factors outside the company’s control—including future market capitalization, regulatory approvals, competitive landscape, intellectual property rights, and overall economic conditions.
Investor and Media Contacts
Conclusion
The delisting from the NYSE marks a pivotal moment for Vicarious Surgical and its investors. Shareholders should closely monitor company communications and developments regarding the potential appeal process, while also considering the implications of trading on the OTCID market. This event is highly price sensitive and may have a material effect on the company’s share value and liquidity in the near term.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with their financial advisors before making investment decisions. The company’s future performance is subject to various risks and uncertainties as detailed above.
View Vicarious Surgical Inc. Historical chart here
